ADDERALL 12.5 Drug Patent Profile

When do Adderall 12.5 patents expire, and when can generic versions of Adderall 12.5 launch?

Adderall 12.5 is a drug marketed by Teva Womens and is included in one NDA.

The generic ingredient in ADDERALL 12.5 is amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate. Twenty-seven suppliers are listed for this compound. Additional details are available on the amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate profile page.

Summary for ADDERALL 12.5

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ADDERALL 12.5

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Womens	ADDERALL 12.5	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	011522-012	Aug 31, 2000		DISCN	Yes	No

International Patents for ADDERALL 12.5

See the table below for patents covering ADDERALL 12.5 around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	6089200
Canada	2378336
European Patent Office	1202739
Japan	2003504406
Mexico	PA02000290	FORMA DE DOSIFICACION ORAL DE LIBERACION INMEDIATA RAPIDA. (RAPID IMMEDIATE RELEASE ORAL DOSAGE FORM.)
World Intellectual Property Organization (WIPO)	0105407

Investment Scenario and Fundamentals Analysis for ADDERALL 12.5 mg

Last updated: February 20, 2026

What Are the Core Financial and Regulatory Aspects?

ADDERALL 12.5 mg is a generic form of the prescription medication containing mixed amphetamine salts, primarily used to treat ADHD and narcolepsy. Its market viability depends on patent status, regulatory environment, manufacturing, and competitive landscape.

Patent and Market Exclusivity Status

• Patent Expiry: The original patent for the branded ADDERALL (marketed by Shire, now part of Takeda) expired in 2017 in the U.S.[1].
• Generic Entry: Several manufacturers entered the market post-patent expiry, leading to increased generic competition.
• Trademark Conflicts: The ADDERALL brand remains protected under trademarks, but the drug itself is available as a generic.

Regulatory Approval and Market Authorization

• FDA Approval: The generic version of ADDERALL 12.5 mg holds FDA approval, in line with regulatory requirements for bioequivalence.
• Manufacturing Requirements: Compliance with Good Manufacturing Practices (GMP) from FDA or equivalent authorities is necessary.
• Market Restrictions: ADHD medications are Schedule II controlled substances, which imposes strict prescribing and dispensing regulations.

Market Dynamics and Revenue Streams

• Market Size: The global ADHD treatment market was valued at approximately USD 11.4 billion in 2020, with continued growth projected at 6-8% annually through 2028.[2]
• Segment Share: Generic formulations like ADDERALL 12.5 mg constitute a significant portion of prescriptions due to price competition.
• Sales Volatility: Shifts in prescribing habits, reimbursement policies, and regulatory changes impact revenue stability.

Manufacturing and Cost Considerations

• Production Costs: Active pharmaceutical ingredient (API) costs are relatively low compared to branded counterparts.
• Pricing Strategies: Pricing is competitive, often aligned with other generics, with margins influenced by market penetration and regulatory compliance costs.
• Supply Chain Risks: Dependence on controlled substance manufacturing complicates logistics and increases regulatory oversight.

Competitive Landscape and Market Share

Company	Market Share (Estimated, 2022)	Notable Products
Teva Pharmaceuticals	35%	Teva’s generic ADDERALL
Sandoz	20%	Sandoz generic amphetamines
Other generic manufacturers	45%	Multiple small players

• Innovative vs. Generic: The drug's patent expiration led to widespread generic substitution, reducing profit margins for originators.
• Emerging Competitors: Companies entering biosimilar and alternative formulations target the same patient population, impacting long-term growth.

Investment Considerations

Strengths

• Large, stable demand driven by ADHD diagnosis rates
• Cost-efficient manufacturing and widespread market acceptance for generics

Risks

• Regulatory changes affecting controlled substance prescriptions
• Price erosion due to increasing generic competition
• Potential for reformulation or alternative therapies reducing demand

Financial Outlook

• Revenue Estimates: Post-patent expiry, annual sales vary but typically range between USD 150 million and USD 300 million for top generic players in the U.S.[3]
• Profit Margins: Gross margins for generics hover around 20-30%, impacted by supply chain costs and competition.
• Growth Potential: Market expansion in emerging countries and increasing ADHD diagnoses support moderate growth.

Regulatory and Legal Factors

• Enhanced oversight on Schedule II substances increases compliance costs.
• Patent litigation and exclusivity periods influence market entry and pricing strategies.
• Changes in prescribing regulations in key markets, notably U.S., can affect sales volumes.

Key Takeaways

• The generic ADDERALL 12.5 mg faces intense competition amid a mature market.
• Revenue depends heavily on regulatory stability and market acceptance.
• Profitability is constrained by low margins typical of generics but compensated by high volume.
• Regulatory risks, especially around Schedule II controlled substances, require ongoing compliance investment.
• Market growth prospects are moderate, driven by increasing ADHD diagnoses and expanding global access.

FAQs

1. What is the current patent status of ADDERALL 12.5 mg?
The original patent expired in 2017; multiple generics are available, reducing exclusivity.

2. How does regulatory oversight affect investments in ADDERALL generics?
Strict regulation of Schedule II substances increases compliance costs and potential legal risks.

3. What are the main competition threats for ADDERALL 12.5 mg?
Market share erosion from numerous generic manufacturers; emerging treatments for ADHD or alternative drug delivery methods.

4. How is market demand for ADDERALL 12.5 mg expected to evolve?
Demand remains relatively stable due to consistent ADHD diagnoses; growth is moderate, influenced by regional prescription patterns.

5. What are the financial risks for investors in generic ADDERALL products?
Price erosion from competition and regulatory changes pose significant risks, potentially reducing margins and revenues.

References

[1] FDA. (2021). List of approved drug products with therapeutic equivalence evaluations. U.S. Food and Drug Administration.

[2] Grand View Research. (2021). ADHD Treatment Market Size, Share & Trends Analysis Report.

[3] EvaluatePharma. (2022). Generic drug sales data and projections.